Tau Degradation Assay
Neurological diseases cause huge social losses and heavy annual economic burdens, so it is urgent to develop new drugs. Equipped with world-leading technology platforms and professional scientific staff, Creative Biolabs provides the novel Tau degradation assay for our clients all over the world.
Tau Degradation in Alzheimer's disease
Alzheimer's disease is the most common type of dementia that induces the brain to shrink and brain cells to die. In AD, pathological forms of tau are transferred between cells and "seed" to accumulate in cytoplasmic tau. Studies have shown that the phosphorylation of tau plays a key role in neurodegenerative tauopathies. In addition, apolipoprotein E (apoE) is also a genetic risk determinant for AD. Using surface plasmon resonance experiments, we verified the high-affinity binding of tau and the tau microtubule-binding domain to LRP1. Furthermore, the phosphorylated form of recombinant tau binds weakly to LRP1, and LRP1-mediated tau uptake is inhibited by apoE. A large body of research data demonstrates that LRP1 acts as an endocytic receptor that binds and processes monomeric tau, ultimately leading to its degradation and promoting the seeding of pathological forms of tau. Cells are exposed to preformed fibril Tau, which triggers Tau phosphorylation and fibril Tau formation in the cell. Therefore, Tau protein tangles have been considered an important pathological hallmark of Alzheimer's disease and a potential therapeutic direction.
Fig.1 Surface-accessible lysine residues available for LRP1 binding on tau protofilament from Alzheimer's disease. (Cooper, et al., 2021)
Tau Degradation Assay
Now Creative Biolabs provides the Tau degradation assay to identify inhibitors for Tau fibrillization in mutant Tau overexpressed cells. According to the Tau degradation assay, it is possible to verify whether the compound can degrade tau protein in human cells. The compound's ability to cross the blood-brain barrier (BBB) can then be further assessed by in vivo experiments. Aggregation of tau proteins, especially hyperphosphorylated tau proteins, may contribute to tauopathies in AD. Therefore, the degradation of tau protein provides new ideas for the treatment of neurological diseases such as AD.
Advantages of our Assay
- Advanced platforms to ensure the best achievement for every single step.
- Fully customizable experimental design to expand beyond standard procedure.
- Reliable lab report with timely updates.
- Affordable price with the best quality.
Equipped with world-leading technology platforms and professional scientific staff, Creative Biolabs can not only provide super high-quality data but also help you establish an AD research pipeline and create new techniques for your own projects. If you are interested in our services, please do not hesitate to contact us for more details.
Reference
- Cooper, J.M.; et al. Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism. Journal of Biological Chemistry. 2021, 296.
